

A SYMPOSIA ON THE PREVENTION & TREATMENT OF OSTEONECROSIS OF THE JAWS:

“A Multidisciplinary Approach for the Oncologist, Dentist & Oral & Maxillofacial Surgeon”

Saturday, December 10th, 2016

12:00 Lunch Conference from 1:00-4:00pm

Emily Morgan Hotel, A DOUBLETREE by Hilton, San Antonio, TX



DISTINGUISHED SPEAKERS

Robert E. Marx, D.D.S

Professor of Surgery, Director of Research
Chief, Division of Oral and Maxillofacial Surgery,
Department of Surgery, University of Miami Miller School of Medicine
Diplomate, American Board of Oral and Maxillofacial Surgery
Miami, FL

Reshma Mahtani, M.D.

Assistant Professor of Medicine,
University of Miami Miller School of Medicine
Sylvester Comprehensive Cancer Center
Deerfield Beach, FL



SPONSORED BY The Medical Educator Consortium

Course Description

This symposia will review the therapeutic indications and mechanisms as well as ONJ, risks for the commonly used bisphosphonates and RANKL inhibitors in metastatic cancer treatment and osteoporosis. Specific case samples will show control of metastatic disease and the slowing of osteoporosis. Others will show the reality of ONJ and how it can be prevented in most cases and managed in others so as not to materially interfere with the treatment of cancer or of osteoporosis.

Osteonecrosis of the Jaw (ONJ) is a known risk when patients receive either bisphosphonate drugs or RANKL-inhibitors. These patients require an understanding and dual management by both medical oncologists and dentists especially oral and maxillofacial surgeons.

The most common drugs to cause ONJ are the ones most effective and most commonly used by oncologists to halt bone dissolution from metastatic cancer deposits and the osteoporosis that cancer chemotherapy may cause. The drugs are IV zoledronic acid, subcutaneous denosumab and oral alendronate. Each has a different bone bioavailability and potency. Moreover, denosumab has a different terminal half-life in bone. Additionally, these drugs affect the jaw ten times more than they affect other bones due to the activity of the jaw, the presence of teeth and/or the wearing of dentures.

Medical oncologists have a knowledge gap in the understanding of the increased bone remodeling rate, the effect of dental disease on the jaws and the impact of surgical procedures on the jaw when the patient have received these medications.

Dentists and oral and maxillofacial surgeons have a knowledge gap concerning the differences between these drugs related to route of administration, half-life in bone and length of treatment.

Additionally, dentist and oral and maxillofacial surgeons are unclear concerning the different prevention and management guidelines required related to each drug.

Course Objectives

- Create an awareness and apply a multi-disciplinary approach of best dosing and treatment schedules for metastatic breast cancer patients;
- Understand the impact of osteonecrosis of the jaws in your patients;
- Recognize the therapeutic value and the various drugs used in the treatment of metastatic breast cancer;
- Describe the prevention of ONJ and treatments used for ONJ;
- Describe the risk for osteoporosis in patients treated for metastatic breast cancer;
- Review the management of osteoporosis in cancer patients and non-cancer patients as well as the ONJ that may result.
- The oncologist will be able to coordinate care with dentists and/or oral and maxillofacial surgeons
- The dental specialist will be able to institute pre-treat preventive dental care to reduce the risk of ONJ
- The oral and maxillofacial surgeons will be able to assess the severity of ONJ and be able to decide when nonsurgical management is indicated and when surgical management is indicated.
- The medical oncologists will be able to decide when a drug holiday is safe to pursue versus situations when it is not.

Accreditation

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Educator Consortium, designates this live activity for a maximum of *4.0 AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty Disclosure Statement

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

Registration

Registration fee:

\$100 Physicians, Dentist & Oral & Maxillofacial Surgeons in Private Practice

\$75 Active Members of the Military, Residents, Fellows, Nurses, Nurse Practitioners and Allied Health Professionals

\$150 Industry Professionals

Refunds must be provided in writing prior to November 1st, 2016. After November 1st, 2016 no Refunds will be provided. All refunds will be charged a \$25.00 administrative fee.

Register online at www.meccinc.com

For more information, contact:

CONFERENCE MANAGEMENT

MECC (Meetings Events & Conference Coordinators, Inc.)

6619 South Dixie Highway #341 Miami, FL 33143

Telephone: 305/663-1628 Office Fax: 305/675-2718

Email: tvalls@meccinc.com Or visit our website at www.meccinc.com

**A SYMPOSIA ON THE PREVENTION & TREATMENT OF OSTEONECROSIS OF THE JAWS:
"A Multidisciplinary Approach for the Oncologist, Dentist & Oral & Maxillofacial Surgeon"
Saturday, December 10th, 2016**

Agenda

11:00am -12:00 noon Registration

12:00 pm Lunch

12:45 pm Course Introduction and Statement of Goals

1:00 pm – 2:15 pm

- A. Indications for Bisphosphonates and RANK Ligand Inhibitors in Breast Cancer Patients
- B. Benefits of Bisphosphonates and RANK Ligand Inhibitors in the Metastatic and Adjunct Setting
- C. Dosing Schedule of Drugs – Impact of Dosing Delays. Modifications of Dosing and Treatment Schedule

***Reshma Mahtani MD
Sylvester Cancer Center
University of Miami Miller School of Medicine***

2:15 pm – 3:30 pm

- A. Drug Induced Osteonecrosis of the Jaws Incidence, Severity, and Initiating Factors. Differences related to each drug.
- B. Prevention of ONJ for Patients on Zoledronate, Denosumab, and Alendronate
- C. Non-surgical Management of ONJ
- D. Surgical Management of ONJ
- E. Special Consideration for Patients with Osteoporosis

***Robert E. Marx, DDS
Division of Oral and Maxillofacial Surgery
University of Miami Miller School of Medicine***

3:30 pm – 4:00 pm Questions and Answers

Dr. Robert E. Marx & Dr. Reshma Mahtani

4:00 pm Meeting Adjourned

Hotel Information



THE EMILY MORGAN a DOUBLETREE BY HILTON

705 East Houston Street

San Antonio, TX 78205

RESERVATIONS | Toll Free 800.824.6674 | emilymorganhotel.com

The Emily Morgan Hotel is an iconic property that blends historic charm and legendary tales with a modern Texas Flair. As the “Official Hotel of the Alamo”, the property exemplifies urban adventure in the heart of San Antonio. The hotel was built in the 1920s and features timeless architecture and intricate Gothic style embellishments that tell an interesting story of the buildings famous history. The stylish and charismatic guest rooms radiate luxury and are enhanced with lavish amenities. The Emily Morgan provides a welcome retreat for both business and leisure travelers.

The Emily Morgan Hotel from an enviable location on Alamo Plaza, steps away from the Alamo and only 2 blocks from the San Antonio River Walk, guest are mesmerized with the unique architectural design, Gothic Revival. This upscale modern boutique hotel is an unparalleled experience that reflects the rich culture, energy, and style of San Antonio. The hotel is located 8 miles from the San Antonio International Airport.

The room block is limited, the hotel is offering special rates during this conference of \$214 plus tax, European plan (no meals). The cutoff date to make reservations is November 9, 2016, after this date reservation are subject to hotel availability.

The Emily Morgan San Antonio - a DoubleTree by Hilton

Group Code: UNIVERSITY OF MIAMI

Booking Link:

https://secure3.hilton.com/en_US/dt/reservation/book.htm?inputModule=HOTEL&ctyhocn=SATEMDT&specplan=CDTUOM&arrival=20161209&departure=20161210&cid=OM,WW,HILTONLINK,EN,DirectLink&fromId=HILTONLINKDIRECT

REGISTRATION FORM

A SYMPOSIA ON THE PREVENTION & TREATMENT OF OSTEONECROSIS OF THE JAWS:

"A Multidisciplinary Approach for the Oncologist, Dentist & Oral & Maxillofacial Surgeon"

Saturday, December 10th, 2016

Emily Morgan Hotel, A DOUBLETREE by Hilton, San Antonio, TX

Register online at www.meccinc.com or FAX to 305/675-2718.

Name _____ Degree _____

Address _____

City _____ State _____ Zip _____

Telephone (____) _____ FAX (____) _____

Email address _____

Specialty _____

Type of Practice: (circle one of the following)

Private

Academic

Hospital

Resident/Fellow

Registration fee:

\$100 - Physicians

\$ 75 –Active Military, Residents, Fellows, Nurses, Nurse Practitioners and Allied Health Professionals

\$150- Industry Professionals

Enclosed is my check in the i/a/o of _____ for registration of this course.

I authorize MECC to charge my credit card i/a/o \$ _____ for registration of this course using the following credit card.

Name on Card _____ Exp. Date _____

Card number _____ CVV _____

Authorized signer _____

If you require special assistance or have specific dietary requirements, please contact MECC, Inc. no later than November 1st, 2016 via email at tvalls@meccinc.com.